Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration

Nature Communications

Volumn 8, Issue , 2017, Pages

  Shin, Seung Min ^a   Choi, Dong Ki ^a,c,d   Jung, Keunok ^a   Bae, Jeomil ^a,c,d   Kim, Ji Sun ^a   Park, Seong Wook ^a   Song, Ki Hoon ^b   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Ajou University School of Medicine   (South Korea)

^c ORUM Therapeutics Inc   (South Korea)

^d Institute for Basic Science   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; GUANOSINE TRIPHOSPHATE; IMMUNOGLOBULIN G1 ANTIBODY; RAS PROTEIN; RT 11; UNCLASSIFIED DRUG; GUANOSINE TRIPHOSPHATASE; HRAS PROTEIN, HUMAN; IMMUNOGLOBULIN G; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; NRAS PROTEIN, HUMAN; PROTEIN P21;

ANTIBODY; CELLS AND CELL COMPONENTS; DRUG; GENE EXPRESSION; INHIBITION; MUTATION; PROTEIN; TUMOR;

3T3 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASPC-1 CELL LINE; BALB/C NUDE MOUSE; COLO 320DM CELL LINE; CONTROLLED STUDY; CYTOSOL; DEVELOPMENT; DOWNSTREAM PROCESSING; DRUG BINDING; DRUG SELECTIVITY; DRUG TARGETING; EMBRYO; FEMALE; GENE TARGETING; GENETIC VARIABILITY; HELA CELL LINE; HL-60 CELL LINE; HT-1080 CELL LINE; HT-29 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; K-562 CELL LINE; LOVO CELL LINE; MCF-7 CELL LINE; MOUSE; MUTANT; NCI-H1299 CELL LINE; NONHUMAN; ONCOGENE RAS; PANC-1 CELL LINE; PROTEIN INTERACTION; SW480 CELL LINE; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER TRANSPLANTATION; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; MUTATION; NEOPLASM; NIH 3T3 CELL LINE; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSOL; GTP PHOSPHOHYDROLASES; HELA CELLS; HL-60 CELLS; HT29 CELLS; HUMANS; IMMUNOGLOBULIN G; K562 CELLS; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; NIH 3T3 CELLS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027874651     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15090     Document Type: Article

References (62)

1. Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J. & Der, C. J. Drugging the undruggable RAS: Mission possible? Nat. Rev. Drug Discov. 13, 828–851 (2014).
2. Stephen, A. G., Esposito, D., Bagni, R. K. & McCormick, F. Dragging ras back in the ring. Cancer Cell 25, 272–281 (2014).
3. Milburn, M. V. et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 247, 939–945 (1990).
4. Vetter, I. R. & Wittinghofer, A. The guanine nucleotide-binding switch in three dimensions. Science 294, 1299–1304 (2001).
5. Prior, I. A., Lewis, P. D. & Mattos, C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457–2467 (2012).
6. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761–774 (2011).
7. Lim, S. M. et al. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. Angew. Chem. Int. Ed. Engl. 53, 199–204 (2014).
8. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548–551 (2013).
9. Shima, F. et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction. Proc. Natl Acad. Sci. USA 110, 8182–8187 (2013).
10. Gonzalez-Perez, V. et al. Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. J. Mol. Signal 5, 2 (2010).
11. Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl Acad. Sci. USA 109, 5299–5304 (2012).
12. Rosnizeck, I. C. et al. Metal-bis(2-picolyl)amine complexes as state 1(T) inhibitors of activated Ras protein. Angew. Chem. Int. Ed. Engl. 51, 10647–10651 (2012).
13. Cromm, P. M., Spiegel, J., Grossmann, T. N. & Waldmann, H. Direct modulation of small GTPase activity and function. Angew. Chem. Int. Ed. Engl. 54, 13516–13537 (2015).
14. Athuluri-Divakar, S. K. et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell 165, 643–655 (2016).
15. Upadhyaya, P. et al. Inhibition of Ras signaling by blocking Ras-effector interactions with cyclic peptides. Angew. Chem. Int. Ed. Engl. 54, 7602–7606 (2015).
16. Leshchiner, E. S. et al. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. Proc. Natl Acad. Sci. USA 112, 1761–1766 (2015).
17. Imai, K. & Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 6, 714–727 (2006).
18. Reichert, J. M. Antibodies to watch in 2016. MAbs 8, 197–204 (2016).
19. Marschall, A. et al. Delivery of antibodies to the cytosol: Debunking the myths. MAbs 6, 943–956 (2014).
20. Tanaka, T., Williams, R. L. & Rabbitts, T. H. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J. 26, 3250–3259 (2007).
21. Tanaka, T. & Rabbitts, T. H. Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth. Oncogene 29, 6064–6070 (2010).
22. Choi, D. K. et al. A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells. MAbs 6, 1402–1414 (2014).
23. Kim, J. S. et al. Quantitative assessment of cellular uptake and cytosolic access of antibody in living cells by an enhanced split GFP complementation assay. Biochem. Biophys. Res. Commun. 467, 771–777 (2015).
24. Kim, J.-S. et al. Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape. J. Control. Release 235, 165–175 (2016).
25. Baek, D. S. & Kim, Y. S. Construction of a large synthetic human Fab antibody library on yeast cell surface by optimized yeast mating. J. Microbiol. Biotechnol. 24, 408–420 (2014).
26. Sydor, J. R., Engelhard, M., Wittinghofer, A., Goody, R. S. & Herrmann, C. Transient kinetic studies on the interaction of Ras and the Ras-binding domain of c-Raf-1 reveal rapid equilibration of the complex. Biochemistry 37, 14292–14299 (1998).
27. Hunter, J. C. et al. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13, 1325–1335 (2015).
28. Kiel, C. et al. Improved binding of raf to Ras.GDP is correlated with biological activity. J. Biol. Chem. 284, 31893–31902 (2009).
29. Linnemann, T., Kiel, C., Herter, P. & Herrmann, C. The activation of RalGDS can be achieved independently of its Ras binding domain. Implications of an activation mechanism in Ras effector specificity and signal distribution. J. Biol. Chem. 277, 7831–7837 (2002).
30. Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103, 931–943 (2000).
31. Fritsch, R. et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 153, 1050–1063 (2013).
32. Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517–531 (2008).
33. Matsumoto, K. et al. Critical roles of interactions among switch I-preceding residues and between switch II and its neighboring alpha-helix in conformational dynamics of the GTP-bound Ras family small GTPases. J. Biol. Chem. 286, 15403–15412 (2011).
34. Hayes, T. K. & Der, C. J. Mutant and wild-type Ras: co-conspirators in cancer. Cancer Discov. 3, 24–26 (2013).
35. Hirasawa, K. et al. Oncolytic reovirus against ovarian and colon cancer. Cancer Res. 62, 1696–1701 (2002).
36. Shirasawa, S., Furuse, M., Yokoyama, N. & Sasazuki, T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260, 85–88 (1993).
37. Fujita-Sato, S. et al. Enhanced MET translation and signaling sustains K-Ras-driven proliferation under anchorage-independent growth conditions. Cancer Res. 75, 2851–2862 (2015).
38. Shi, X. H., Liang, Z. Y., Ren, X. Y. & Liu, T. H. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther. 16, 227–236 (2009).
39. Holig, P. et al. Novel RGD lipopeptides for the targeting of liposomes to integrin-expressing endothelial and melanoma cells. Protein Eng. Des. Sel. 17, 433–441 (2004).
40. Desgrosellier, J. S. & Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9–22 (2010).
41. Unverdorben, F. et al. Pharmacokinetic properties of IgG and various Fc fusion proteins in mice. MAbs 8, 120–128 (2016).
42. Chong, C. R. & Janne, P. A. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389–1400 (2013).
43. Lievre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992–3995 (2006).
44. Wild, R. et al. Cetuximab preclinical antitumor activity (monotherapy and combination based) is not predicted by relative total or activated epidermal growth factor receptor tumor expression levels. Mol. Cancer Ther. 5, 104–113 (2006).
45. Fujioka, A. et al. Dynamics of the Ras/ERK MAPK cascade as monitored by fluorescent probes. J. Biol. Chem. 281, 8917–8926 (2006).
46. Smith, S. J. & Rittinger, K. Preparation of GTPases for structural and biophysical analysis. Methods Mol. Biol. 189, 13–24 (2002).
47. Lee, C. H. et al. Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo. Proc. Natl Acad. Sci. USA 107, 9567–9571 (2010).
48. Baek, D. S. & Kim, Y. S. Humanization of a phosphothreonine peptide-specific chicken antibody by combinatorial library optimization of the phosphoepitope-binding motif. Biochem. Biophys. Res. Commun. 463, 414–420 (2015).
49. Choi, H. J., Kim, Y. J., Choi, D. K. & Kim, Y. S. Engineering of immunoglobulin fc heterodimers using yeast surface-displayed combinatorial Fc library screening. PLoS ONE 10, e0145349 (2015).
50. Nakanishi, T. et al. Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy. Protein Eng. Des. Sel. 26, 113–122 (2013).
51. Hutchison, 3rd C. A., Nordeen, S. K., Vogt, K. & Edgell, M. H. A complete library of point substitution mutations in the glucocorticoid response element of mouse mammary tumor virus. Proc. Natl Acad. Sci. USA 83, 710–714 (1986).
52. Shin, T. H. et al. Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy. Mol. Cancer Ther. 13, 651–661 (2014).
53. Kim, Y. J. et al. Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis. J. Control Release 216, 56–68 (2015).
54. Lee, H. W. et al. Real-time single-molecule co-immunoprecipitation analyses reveal cancer-specific Ras signalling dynamics. Nat. Commun. 4, 1505 (2013).
55. Kim, Y. J., Jung, K., Baek, D. S., Hong, S. S. & Kim, Y. S. Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin beta1-driven Src-Akt bypass signaling. Oncogene doi:10.1038/onc.2016.407 (2016).
56. de Araújo, M. E., Lamberti, G. & Huber, L. A. Isolation of Early and Late Endosomes by Density Gradient Centrifugation. Cold Spring Harb. Protoc. 2015, 1013–1016 (2015).
57. Brummelkamp, T. R., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243–247 (2002).
58. Bivona, T. G., Quatela, S. & Philips, M. R. Analysis of Ras activation in living cells with GFP-RBD. Methods Enzymol. 407, 128–143 (2006).
59. Pukac, L. et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo Br. J. Cancer 92, 1430–1441 (2005).
60. Kawamoto, M., Horibe, T., Kohno, M. & Kawakami, K. A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer 11, 359 (2011).
61. Fetics, S. K. et al. Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 23, 505–516 (2015).
62. Vetter, I. R. et al. Structural and biochemical analysis of Ras-effector signaling via RalGDS. FEBS Lett. 451, 175–180 (1999).